Success Metrics

Active Trials
4(57%)

Phase Distribution

Ph phase_1
1
14%
Ph phase_2
5
71%
Ph phase_3
1
14%

Phase Distribution

1

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
5(71.4%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

7

all time

Status Distribution
Active(7)

Detailed Status

Not yet recruiting3
Recruiting3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
4
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 25 (71.4%)
Phase 31 (14.3%)

Trials by Status

not_yet_recruiting343%
recruiting343%
active_not_recruiting114%

Recent Activity

4 active trials
Showing 5 of 7
not_yet_recruitingphase_2

Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC

NCT07549061
recruitingphase_2

Vebreltinib for Advanced or Metastatic CCS

NCT07153887
recruitingphase_2

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

NCT06574347
recruitingphase_1

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

NCT06343064
not_yet_recruitingphase_3

Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

NCT06970782
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07549061Phase 2

Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC

Not Yet Recruiting
NCT07153887Phase 2

Vebreltinib for Advanced or Metastatic CCS

Recruiting
NCT06574347Phase 2

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Recruiting
NCT06343064Phase 1

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Recruiting
NCT06970782Phase 3

Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

Not Yet Recruiting
NCT06827145Phase 2

Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

Active Not Recruiting
NCT06644313Phase 2

Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

Not Yet Recruiting

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7